Highlights IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm Other stock markets 11:29:43 2024-05-31 am EDT			5-day change	1st Jan Change
15.6 ^SEK	-0.95%		-0.95%	+108.00%

May. 27	Sweden’s IRLAB Therapeutics Names New CEO	MT
May. 27	IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IRLAB Therapeutics AB Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757	May. 22	CI
IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	May. 07	CI
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757	May. 06	CI
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	Mar. 22	CI
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	Mar. 19	CI
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	Feb. 22	CI
IRLAB Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 07	CI
IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines	Feb. 06	CI
IRLAB Is Granted an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	Jan. 03	CI
IRLAB Therapeutics AB Receives Grant from the Michael J. Fox Foundation to Support Development of IRL 757 for the Treatment of Apathy	Dec. 21	CI
IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I	Dec. 21	CI
IRLAB Therapeutics AB Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program	Dec. 18	CI
Irlab Therapeutics Secures European Patent for Parkinson’s Disease Drug Candidate	Dec. 12	MT
IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection	Dec. 12	CI
IRLAB Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-25	CI
IRLAB Therapeutics AB Signs With Clintrex and ProPharma Group Phase III Regulatory US Consultants to Support Preparation for Mesdopetam?s end-of-Phase 2 Meeting with the US FDA	23-10-10	CI
IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam?s Clinical Phase IIb Study in Parkinson?s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen	23-08-21	CI
IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development	23-08-21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Highlights

Filters